Blueprint Medicines’ shares have gained 13.8% year to date against the industry’s 3.3% decline. Image Source ... a Zacks expert as the #1 favorite stock to gain +100% or more in 2024.

All in all, this was a great start for Blueprint Medicines following the launch of Ayvakit, and the leading cancer-treatment stock is responding in kind. Steve Symington has no position in any ...

Image Source: Zacks Investment Research Blueprint is conducting an early-stage ... In three months, CytomX Therapeutics’ ...

Shares of Blueprint Medicines BPMC rallied 18.2% on ... In three months, CytomX Therapeutics’ stock has lost 20.8%. CTMX’s earnings beat estimates in two of the trailing four quarters and ...